Hence, Pharmac temporarily funded liraglutide (Victoza) from March 1, 2023
The common link is that GLP-1s activate receptors that then work on driving down metabolic risk factors through the following mechanisms: Enhancing glucose dependent insulin secretion Slowing gastric emptying and decreasing appetite Reducing postprandial glucagon and food intake UpToDate 2 : (1) ingestion of food results in (2) release of gastrointestinal peptides (GLP-1 and GIP: glucose-dependent insulinotropic polypeptide, gastric inhibitory peptide) and (3) pancreatic beta cell hormones (insulin and amylin)
GI Status: Most symptoms resolving
Demography, clinical characteristics, psychological profiles, treatment and long-term follow-up of patients with gastroparesis
Read the full consensus here: AJCN Nutritional Priorities to Support GLP-1 Therapy Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society ajcn.nutrition.org To view or add a comment, sign in More from this author Explore content categories